MetaCap

Journey Medical (DERM) vs NeOnc Technologies (NTHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeOnc Technologies (NTHI) has outperformed Journey Medical (DERM) over the past year, losing 46.2% versus a loss of 55.8%. Journey Medical is the larger company by market cap ($93.2 million vs $90.9 million), about 1.0 times the size. Journey Medical converts more of its revenue into profit, with a net margin of -18.5% versus -155404.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DERM-55.76%NTHI-46.25%
+90%+13%-64%
Nov 21, 20251 yearNov 20, 2026
DERM-45.99%NTHI-80.97%
+56%-17%-90%
Mar 24, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DERM versus NTHI key metrics
MetricDERMNTHI
Share price$3.30$3.15
Market cap$93.16M$90.88M
1-day change-7.04%-9.48%
YTD return-57.20%-61.91%
1-year return-55.76%-46.25%
5-year return-61.13%—
EPS (TTM)$-0.18$-1.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$61.86M$39.99K
Revenue growth (YoY)+10.20%-51.82%
Net income (latest FY)$-11.43M$-62.15M
Gross margin66.17%—
Operating margin-13.21%-145637.52%
Net margin-18.48%-155404.38%
52-week high$9.56$11.38
52-week low$3.21$2.50
Distance from 52-week high-65.46%-72.31%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+286.36%+439.68%
Average volume190.39K187.23K
Shares outstanding22.23M28.85M
Employees585
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Journey Medical is more profitable, keeping -18.5 cents of every revenue dollar as net income versus -155404.4 cents for NeOnc Technologies.
  • Journey Medical grew revenue faster in its latest fiscal year (+10.20% vs -51.82%).

About Journey Medical

DERM stock →

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

About NeOnc Technologies

NTHI stock →

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

DERM vs NTHI FAQ

Which is bigger, Journey Medical or NeOnc Technologies?

Journey Medical (DERM) is larger, with a market capitalization of $93.16M compared with $90.88M for NeOnc Technologies (NTHI).

Which stock has performed better over the past year, DERM or NTHI?

NTHI returned -46.25% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.

Are Journey Medical and NeOnc Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons